Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 1

Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

December 19, 2024

By John Kitchens, MD
Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth

Opinion

Video

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

Now Viewing

EP: 1.Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP: 2.Advantages of the Molecular Structure of Aflibercept

EP: 3.Treat-and-Extend Strategy With Aflibercept

EP: 4.Assessing New Therapies for Retinal Diseases

EP: 5.Significance of the Higher Molar Dose of Aflibercept 8 mg

EP: 6.Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP: 7.Patient Selection for Aflibercept 8 mg

EP: 8.Faricimab Molecular Design and Role of Ang-2

EP: 9.Outcomes with Raricimab and Choosing Between the New Therapies

EP: 10.Safety Profile of New Therapies

EP: 11.Perspectives on the Usefulness of Real-world Data

EP: 12.Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP: 13.Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!